IPO
Life sciences company eSense-Lab Ltd is pleased to report its preliminary financial results for the year ending 31 December 2018, along with the attached Appendix 4E.
Esperion provided bempedoic acid franchise development program updates and financial results for the fourth quarter and year ended December 31, 2018.
Todos Medical Ltd., a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced that it has raised $1,350,500 from private investors.
MDxHealth SA, announced its business update and financial results for the year ended December 31, 2018 and provided its strategic outlook for 2019.
Althea Group Holdings Limited is pleased to provide its Half Year Financial Report and Appendix 4D.
Loos, France-based Genfit announced it is planning an initial public offering (IPO) to raise $100 million. Genfit is a late-stage biopharma company focused on developing therapeutics for metabolic and liver diseases. The area that has the most interest is nonalcoholic steatohepatitis, or NASH.
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
GENFIT announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, each representing one ordinary share, in the United States, and a concurrent private placement of its ordinary shares in Europe and other countries outside of the United States and Canada.
Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN
The past year, 2018, was in many ways a decisive year for Promore Pharma
PRESS RELEASES